News25/Ratings12
News · 26 weeks78-25%
2025-10-262026-04-19
Mix3490d
- Insider16(47%)
- SEC Filings12(35%)
- Other6(18%)
Latest news
25 items- PRDisc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual MeetingWATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of myelofibrosis (MF) in an oral abstract session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held in Chicago, IL on May 29-June 2, 2026. "Initial data from the RALLY-MF trial showed anemia response rates that are unprecedented in the hard-to-treat myelofibrosis population," said Jo
- INSIDERSEC Form 4 filed by Savage William Jacob4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERSEC Form 4 filed by Franchi Jean M.4 - Disc Medicine, Inc. (0001816736) (Issuer)
- PRDisc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic ProtoporphyriaLast participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP)The study size was expanded to 183 participants due to patient and physician demandResults of the APOLLO study are expected in Q4 2026 WATERTOWN, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that the last participant has been randomized and dosed in the pivotal Phase 3 APOLLO trial of bitopertin in EPP. Originally planned as an N=150 stud
- INSIDERChief Medical Officer Savage William Jacob sold $486,069 worth of shares (7,378 units at $65.88), decreasing direct ownership by 8% to 85,211 units (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- PRChronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsightThe chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (Boehringer Ingelheim), Lorundrostat (Mineralys Therapeutics), Rilparencel (ProKidney), DISC-0974 (Disc Medicine), Vonsetamig (Regeneron Pharmaceuticals), and others will further boost the market growth.LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney Disease Market Insights repor
- SECSEC Form 144 filed by Disc Medicine Inc.144 - Disc Medicine, Inc. (0001816736) (Subject)
- INSIDERChief Financial Officer Franchi Jean M. sold $24,377 worth of shares (353 units at $69.06), decreasing direct ownership by 0.49% to 70,990 units (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- SECDisc Medicine Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities8-K - Disc Medicine, Inc. (0001816736) (Filer)
- SECSEC Form S-8 filed by Disc Medicine Inc.S-8 - Disc Medicine, Inc. (0001816736) (Filer)
- SECSEC Form 10-K filed by Disc Medicine Inc.10-K - Disc Medicine, Inc. (0001816736) (Filer)
- SECDisc Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Disc Medicine, Inc. (0001816736) (Filer)
- PRDisc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatePursuing a traditional approval path for bitopertin in erythropoietic protoporphyria (EPP); Phase 3 APOLLO study is expected to complete enrollment in March 2026 with topline data expected in Q4 2026Initial data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) presented at the American Society of Hematology (ASH) conference demonstrating meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status or concomitant JAK inhibitor therapy useProgressing ongoing Phase 2 study of DISC-3405 in polycythemia vera (PV) and initiated a Phase 1b study of DISC-3405 in sickle cell disease (SCD) in Q4 2025, with data from both studi
- SECSEC Form 144 filed by Disc Medicine Inc.144 - Disc Medicine, Inc. (0001816736) (Subject)
- PRDisc Medicine to Participate in Upcoming Investor ConferencesWATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at two upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd at 9:50 a.m. ET in Boston, MA.Leerink Global Healthcare Conference on Monday, March 9th at 3:40 p.m. ET in Miami, FL. Disc management will be participating in investor meetings during the above conferences, as well as the Jefferies Biotech on the Beach Summit on March 1
- INSIDERChief Financial Officer Franchi Jean M. sold $719,727 worth of shares (11,156 units at $64.51), decreasing direct ownership by 14% to 71,343 units (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- SECSEC Form 144 filed by Disc Medicine Inc.144 - Disc Medicine, Inc. (0001816736) (Subject)
- INSIDERChief Legal Officer Khara Rahul sold $179,340 worth of shares (2,853 units at $62.86), decreasing direct ownership by 5% to 52,173 units (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERChief Commercial Officer Stephenson Pamela sold $347,679 worth of shares (5,531 units at $62.86), decreasing direct ownership by 6% to 80,998 units (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERChief Medical Officer Savage William Jacob sold $204,672 worth of shares (3,256 units at $62.86), decreasing direct ownership by 3% to 92,589 units (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERChief Operating Officer Yu Jonathan Yen-Wen sold $203,101 worth of shares (3,231 units at $62.86), decreasing direct ownership by 6% to 54,324 units (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- INSIDERChief Executive Officer Quisel John D sold $833,775 worth of shares (13,264 units at $62.86), decreasing direct ownership by 6% to 226,064 units (SEC Form 4)4 - Disc Medicine, Inc. (0001816736) (Issuer)
- SECSEC Form 144 filed by Disc Medicine Inc.144 - Disc Medicine, Inc. (0001816736) (Subject)
- SECSEC Form 144 filed by Disc Medicine Inc.144 - Disc Medicine, Inc. (0001816736) (Subject)
- SECSEC Form 144 filed by Disc Medicine Inc.144 - Disc Medicine, Inc. (0001816736) (Subject)